Filing Details
- Accession Number:
- 0001104659-24-034673
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-14 20:54:37
- Reporting Period:
- 2024-03-13
- Accepted Time:
- 2024-03-14 20:54:37
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1781983 | Aprea Therapeutics Inc. | APRE | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1716213 | P. John Hamill | 3805 Old Easton Road Doylestown PA 18902 | Srvp/Cfo/Prin Fin & Acct Ofcr | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-03-13 | 1,010 | $7.29 | 15,503 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Tranche A Warrant | Acquisiton | 2024-03-13 | 505 | $0.00 | 505 | $0.00 |
| Common Stock | Tranche B Warrant | Acquisiton | 2024-03-13 | 505 | $0.00 | 505 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 505 | 2024-03-13 | No | 4 | P | Direct | |
| 505 | 2024-03-13 | No | 4 | P | Direct |
Footnotes
- The exercise price of the Tranche A Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share.
- Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
- The exercise price of the Tranche B Warrants is as follows: 505 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share.
- Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred.
- The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above.
Billionaire Hedge Funds
